• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
【24h】

A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.

机译：一种新型的二肽基肽酶4抑制剂阿格列汀（SYR-322）在患有磺酰脲类引起的继发性衰竭的糖尿病大鼠中有效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS: Loss of efficacy over time or secondary failure occurs somewhat often and remains a major concern of sulfonylurea (SU) therapy. In this study, we investigated the benefits of alogliptin, an oral, potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in a rat model exhibiting SU secondary failure. MAIN METHODS: Neonatally streptozotocin-induced diabetic rats (N-STZ-1.5 rats), a non-obese model of type 2 diabetes, were used in these studies. The effects of alogliptin on DPP-4 activity and glucagon-like peptide 1 (GLP-1) concentration were determined by measuring their levels in plasma. In addition, the effects of alogliptin on an oral glucose tolerance test were investigated by using an SU secondary failure model. KEY FINDINGS: Alogliptin dose dependently suppressed plasma DPP-4 activity leading to an increase in the plasma active form of GLP-1 and improved glucose excursion in N-STZ-1.5 rats. Repeated administration of glibenclamide resulted in unresponsiveness or loss of glucose tolerance typical of secondary failure. In these rats, alogliptin exhibited significant improvement of glucose excursion with significant increase in insulin secretion. By contrast, glibenclamide and nateglinide had no effect on the glucose tolerance of these rats. SIGNIFICANCE: The above findings suggest that alogliptin was effective at improving glucose tolerance and therefore overcoming SU induced secondary failure in N-STZ-1.5 rats.
机译：目的：随着时间的流逝，疗效会下降或继发性衰竭，这仍然是磺脲类（SU）治疗的主要问题。在这项研究中，我们研究了口服，有效和高度选择性的二肽基肽酶-4（DPP-4）抑制剂阿格列汀在表现出SU继发性衰竭的大鼠模型中的益处。主要方法：本研究使用了新生的链脲佐菌素诱导的糖尿病大鼠（N-STZ-1.5大鼠），它是非肥胖的2型糖尿病模型。通过测量血浆中阿格列汀对DPP-4活性和胰高血糖素样肽1（GLP-1）浓度的影响。另外，通过使用SU继发性衰竭模型研究了阿格列汀对口服葡萄糖耐量测试的影响。主要发现：阿格列汀剂量依赖性地抑制血浆DPP-4活性，从而导致N-STZ-1.5大鼠血浆活性形式的GLP-1增加，并改善了葡萄糖偏移。重复给予格列本脲会导致继发性衰竭典型的无反应性或葡萄糖耐量下降。在这些大鼠中，阿格列汀显示葡萄糖偏移显着改善，胰岛素分泌显着增加。相比之下，格列本脲和那格列奈对这些大鼠的葡萄糖耐量没有影响。意义：上述发现表明，阿格列汀可有效改善葡萄糖耐量，从而克服SU诱导的N-STZ-1.5大鼠继发性衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号